tiprankstipranks
Advertisement
Advertisement

MXCT Stock Latest News

MaxCyte enters technology license partnership with Genentech
The FlyMaxCyte enters technology license partnership with Genentech
1d ago
CHRO
MXCT
MaxCyte Shareholders Reelect Directors and Ratify Auditor
PremiumCompany Announcements
MaxCyte Shareholders Reelect Directors and Ratify Auditor
1M ago
8K
MXCT
MaxCyte Regains Nasdaq Compliance After Bid Price Recovery
PremiumCompany Announcements
MaxCyte Regains Nasdaq Compliance After Bid Price Recovery
1M ago
8K
MXCT
MaxCyte (MXCT) Earnings Call: Cash-Rich, Growth Delayed
PremiumCompany Announcements
MaxCyte (MXCT) Earnings Call: Cash-Rich, Growth Delayed
2M ago
MXCT
MaxCyte reports Q1 EPS (4c), consensus (9c)
PremiumThe Fly
MaxCyte reports Q1 EPS (4c), consensus (9c)
2M ago
MXCT
MaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M
PremiumThe FlyMaxCyte backs FY26 revenue view $30M-$32M, consensus $30.83M
2M ago
MXCT
MaxCyte Reports Q1 2026 Results, Launches Share Buyback
Premium
Company Announcements
MaxCyte Reports Q1 2026 Results, Launches Share Buyback
2M ago
8K
MXCT
Balanced Hold on MaxCyte: Weighing Repeated Revenue Misses and Soft 2026 Outlook Against Strong Cash Position and Emerging Platform Upside
Premium
Ratings
Balanced Hold on MaxCyte: Weighing Repeated Revenue Misses and Soft 2026 Outlook Against Strong Cash Position and Emerging Platform Upside
4M ago
MXCT
MaxCyte Appoints New Chief Financial Officer Ahuja
PremiumCompany Announcements
MaxCyte Appoints New Chief Financial Officer Ahuja
4M ago
8K
MXCT
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access
PremiumCompany Announcements
MaxCyte Faces Nasdaq Delisting Risk as Share Price Slump Threatens Liquidity and Capital Access
4M ago
MXCT
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside
PremiumCompany Announcements
MaxCyte Earnings Call Weighs Short‑Term Pain, Long‑Term Upside
4M ago
MXCT
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
PremiumThe Fly
MaxCyte price target lowered to $5 from $7 at Craig-Hallum
4M ago
MXCT
MaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
PremiumCompany AnnouncementsMaxCyte Reports Lower 2025 Revenue, Provides 2026 Outlook
4M ago
8K
MXCT
MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M
Premium
The Fly
MaxCyte sees FY26 revenue $30M-$32M, consensus $38.41M
4M ago
MXCT
MaxCyte reports Q4 EPS (9c), consensus (8c)
Premium
The Fly
MaxCyte reports Q4 EPS (9c), consensus (8c)
4M ago
MXCT
MaxCyte appoints Parmeet Ahuja as CFO
PremiumThe Fly
MaxCyte appoints Parmeet Ahuja as CFO
4M ago
A
MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price
PremiumCompany Announcements
MaxCyte Faces Nasdaq Noncompliance Over Minimum Bid Price
4M ago
8K
MXCT
MaxCyte announced the launch of ExPERT DTx
PremiumThe Fly
MaxCyte announced the launch of ExPERT DTx
5M ago
MXCT
MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M
PremiumThe Fly
MaxCyte sees Q4 core revenue $6.6M-$6.7M, consensus $9.3M
6M ago
MXCT
MaxCyte management to meet with Craig-Hallum
PremiumThe FlyMaxCyte management to meet with Craig-Hallum
8M ago
MXCT
MaxCyte CFO Douglas Swirsky to transition out of role
Premium
The Fly
MaxCyte CFO Douglas Swirsky to transition out of role
8M ago
MXCT
MaxCyte reiterates FY25 revenue guidance flat to down 10% vs. last year
Premium
The Fly
MaxCyte reiterates FY25 revenue guidance flat to down 10% vs. last year
8M ago
MXCT

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >